F-star Therapeutics Net Income

The latest net income for FSTX is $-45M as of September 2022. That compares with $-45M in the prior-year period — down 0.3% year over year. That is below the Healthcare sector average of $16B. Investors often review this figure alongside F-star Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, FSTX's net income moved from $-45M to $-45M — a 0.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in F-star Therapeutics's operating scale or balance-sheet position.

Against Healthcare companies, FSTX currently prints $-45M for net income, while the sector average sits near $16B. That is roughly 100.3% below the sector mean. Large gaps often invite a closer look at F-star Therapeutics's growth, margins, and balance sheet.

A net income figure of $-45M for FSTX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $16B. Explore the charts below for those layers of context.

After noting FSTX's net income ($-45M), review year-over-year change from $-45M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.